Media
Press releases
Quotient Limited Announces the Completion of the SARS-CoV-2 Antibody Test Development
JERSEY, Channel Islands, April 06, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today announced the completion of the development phase of a microarray based SARS-CoV-2 (COVID-19) antibody test…
Quotient Limited to Host Investor Information Conference Call and Live Webcast
Quotient Limited Reports Concordance Data from Extended Serological Disease Screening Benchmark Study
Quotient Limited Announces CE Mark Approval for Initial Serological Disease Screening Microarray
Quotient Limited Provides an Update on Recent MosaiQ Milestone Achievements together with Third Quarter Fiscal 2020 Results
Quotient Limited to Report Third Quarter 2020 Financial Results and Host Conference Call
Quotient Limited Provides an Update on Recent Milestone Achievements for its MosaiQ Multimodality Multiplexing Diagnostic Platform
JERSEY, Channel Islands, Jan. 10, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today announced the commencement of the EU field trial activities for the extended Immunohematology (IH) microarray…
Quotient Announces Appointment of New Chief Financial Officer Peter Buhler and Chief Operating Officer Ed Farrell
JERSEY, Channel Islands, Jan. 07, 2020 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the planned appointment of Peter Buhler as Chief Financial Officer (CFO) replacing Chris Lindop, the current CFO who plans to retire in May 2020. Mr.…
Quotient Limited Reports Concordance Data from MDS Concept Study
JERSEY, Channel Islands, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today reported positive concordance data for its MosaiQ™ Multiplex Molecular Disease Screening (MDS) Microarray…
Quotient Limited to Participate in the Jefferies 2019 London Healthcare Conference
JERSEY, Channel Islands, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company’s Chief Executive Officer, Franz Walt, the Company’s President of R&D and Manufacturing, Ed Farrell, and the Company’s Chief…